103 related articles for article (PubMed ID: 305960)
1. Suppression of C3 rosette formation by serum from patients with systemic lupus erythematosus. A corollary of disease activity.
Scheinberg MA; Israel Filho G; Mendes NF; Vertzman L
J Rheumatol; 1978; 5(1):19-25. PubMed ID: 305960
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of complement-dependent lymphocyte rosette formation by sera of patients with chronic glomerulonephritis.
Gluckman JC; Beaufils H; Sanchez F
Clin Exp Immunol; 1976 Nov; 26(2):247-52. PubMed ID: 991456
[TBL] [Abstract][Full Text] [Related]
3. Autologous rosette formation in systemic lupus erythematosus.
Bodolay E; Szegedi G
Acta Med Hung; 1983; 40(2-3):81-9. PubMed ID: 6608094
[TBL] [Abstract][Full Text] [Related]
4. Decreased circulating thymus-derived cells with receptors for the Fc portion of immunoglobulin G in systemic lupus erythematosus.
Alarcón-Segovia D; Ruíz-Argüelles A
J Clin Invest; 1978 Dec; 62(6):1390-4. PubMed ID: 311785
[TBL] [Abstract][Full Text] [Related]
5. Suppression of Fc Receptor and C4.C3 receptors of the granulocytes from patients with systemic lupus erythematosus.
Shingu M; Todoroki T; Sakai K; Nobunaga M
J Rheumatol; 1981; 8(6):910-6. PubMed ID: 7328566
[TBL] [Abstract][Full Text] [Related]
6. Effect of plasmapheresis on cellular immunity abnormalities in patients with systemic lupus erythematosus.
Bonomini V; Vangelista A; Frascà GM; Nanni-Costa A; Borgnino LC
Clin Nephrol; 1984 Sep; 22(3):121-6. PubMed ID: 6237815
[TBL] [Abstract][Full Text] [Related]
7. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
8. Reduced Fc-receptor bearing cells in peripheral bloods of patients with systemic lupus erythematosus and in rheumatoid synovial fluids.
Nakai H; Morito T; Tanimoto K; Horiuchi Y
J Rheumatol; 1977; 4(4):405-13. PubMed ID: 415139
[TBL] [Abstract][Full Text] [Related]
9. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
10. Activation of the alternative complement pathway in systemic lupus erythematosus.
Wilson MR; Arroyave CM; Nakamura RM; Vaughan JH; Tan EM
Clin Exp Immunol; 1976 Oct; 26(1):11-20. PubMed ID: 826360
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome.
Figueredo MA; Rodriguez A; Ruiz-Yagüe M; Romero M; Fernandez-Cruz A; Gomez-de la Concha E; Patiño R
J Rheumatol; 2006 Oct; 33(10):1980-6. PubMed ID: 17014014
[TBL] [Abstract][Full Text] [Related]
12. Correlation of serum measures of nitric oxide production with lupus disease activity.
Gilkeson G; Cannon C; Oates J; Reilly C; Goldman D; Petri M
J Rheumatol; 1999 Feb; 26(2):318-24. PubMed ID: 9972965
[TBL] [Abstract][Full Text] [Related]
13. Serum-induced enhancement of peripheral blood mononuclear cell mediated cytotoxicity towards human target cells in systemic lupus erythematosus.
Wright JK; Penning CA; Ashby JC; Cunningham J; Rowell NR; Hughes P
J Clin Lab Immunol; 1983 Jun; 11(2):81-5. PubMed ID: 6876144
[TBL] [Abstract][Full Text] [Related]
14. Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus.
Sekita K; Doi T; Muso E; Yoshida H; Kanatsu K; Hamashima Y
Clin Exp Immunol; 1984 Mar; 55(3):487-94. PubMed ID: 6608422
[TBL] [Abstract][Full Text] [Related]
15. Loss of suppressor T-lymphocyte function in patients with systemic lupus erythematosus (SLE).
Morimoto C
Clin Exp Immunol; 1978 Apr; 32(1):125-33. PubMed ID: 352583
[TBL] [Abstract][Full Text] [Related]
16. [Serum factors inhibiting cellular immunity in systemic lupus erythematosus].
Lavalle C; Alcocer J; Gudiño J; Fraga A
Prensa Med Mex; 1978; 43(1-2):16-20. PubMed ID: 309127
[TBL] [Abstract][Full Text] [Related]
17. [Immune rosette inhibiting activity of serum from patients with chronic lupus erythematosus treated with chloroquin].
Nagy E; Szegedi G; Tamási P; Sonkoly I
Dermatol Monatsschr; 1978 Jun; 164(6):408-10. PubMed ID: 308469
[No Abstract] [Full Text] [Related]
18. Deficiencies in suppressor T cell activity seen in patients with active systemic lupus erythematosus are due to the dilution of normally functioning suppressor T cells by nonsuppressor T cells.
Sakane T; Takada S; Suzuki N; Tsuchida T; Murakawa Y; Ueda Y
J Immunol; 1986 Dec; 137(12):3809-13. PubMed ID: 2946769
[TBL] [Abstract][Full Text] [Related]
19. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.
Adu D; Williams DG
Clin Exp Immunol; 1984 Mar; 55(3):495-501. PubMed ID: 6705265
[TBL] [Abstract][Full Text] [Related]
20. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
